Docetaxel is effective in heavily pretreated patients with disseminated nasopharyngeal carcinoma

Annals of Oncology

Volumn 22, Issue 3, 2011, Pages 718-722

  Ngeow, J ^a   Lim, W T ^a   Leong, S S ^a   Ang, M K ^a   Toh, C K ^a   Gao, F ^a   Chowbay, B ^a   Tan, E H ^a  

^a DIVISION OF MEDICAL ONCOLOGY   (Singapore)

Author keywords

Docetaxel; Metastatic; Nasopharyngeal cancer

Indexed keywords

CYTOTOXIC AGENT; DEXAMETHASONE; DOCETAXEL; FLUOROURACIL; GEMCITABINE; IRINOTECAN; PACLITAXEL; PLATINUM DERIVATIVE;

ADULT; AGED; ANEMIA; ARTICLE; BLOOD TOXICITY; CANCER RECURRENCE; CLINICAL ARTICLE; CONTROLLED STUDY; DIARRHEA; DISSEMINATED CANCER; DRUG EFFICACY; DRUG FATALITY; DRUG TOLERABILITY; EPIPHORA; FATIGUE; FEMALE; HISTOPATHOLOGY; HUMAN; LIVER TOXICITY; LUNG EMBOLISM; MALE; METASTASIS POTENTIAL; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; MYALGIA; NASOPHARYNX CARCINOMA; NEUROPATHY; NEUTROPHIL COUNT; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PALLIATIVE THERAPY; PNEUMONIA; PRIORITY JOURNAL; QUALITY OF LIFE; QUESTIONNAIRE; SCORING SYSTEM; SIDE EFFECT; THROMBOCYTE COUNT; TREATMENT DURATION; TREATMENT RESPONSE;

ADULT; AGED; ANTINEOPLASTIC AGENTS; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; NASOPHARYNGEAL NEOPLASMS; NEOPLASM METASTASIS; PALLIATIVE CARE; QUALITY OF LIFE; TAXOIDS; TREATMENT FAILURE;

EID: 79952020559     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdq425     Document Type: Article

References (19)

1. Wee J, Tan EH, Tai BC et al. Randomized trial of radiotherapy versus concurrent chemoradiotherapy followed by adjuvant chemotherapy in patients with American Joint Committee on Cancer/International Union against cancer stage III and IV nasopharyngeal cancer of the endemic variety. J Clin Oncol 2005; 23: 6730-6738.
2. Chan AT, Teo PM, Ngan RK et al. Concurrent chemotherapy-radiotherapy compared with radiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: progression-free survival analysis of a phase III randomized trial. J Clin Oncol 2002; 20: 2038-2044.
3. Au E, Tan EH, Ang PT. Activity of paclitaxel by three-hour infusion in Asian patients with metastatic undifferentiated nasopharyngeal cancer. Ann Oncol 1998; 9: 327-329.
4. Foo KF, Tan EH, Leong SS et al. Gemcitabine in metastatic nasopharyngeal carcinoma of the undifferentiated type. Ann Oncol 2002; 13: 150-156.
5. Poon D, Chowbay B, Cheung YB et al. Phase II study of irinotecan (CPT-11) as salvage therapy for advanced nasopharyngeal carcinoma. Cancer 2005; 103: 576-581.
6. Tan EH, Khoo KS, Wee J et al. Phase II trial of a paclitaxel and carboplatin combination in Asian patients with metastatic nasopharyngeal carcinoma. Ann Oncol 1999; 10: 235-237.
7. Rivera E, Mejia JA, Arun BK et al. Phase 3 study comparing the use of docetaxel on an every-3-week versus weekly schedule in the treatment of metastatic breast cancer. Cancer 2008; 112: 1455-1461.
8. Gervais R, Ducolone A, Breton JL et al. Phase II randomised trial comparing docetaxel given every 3 weeks with weekly schedule as second-line therapy in patients with advanced non-small-cell lung cancer (NSCLC). Ann Oncol 2005; 16: 90-96.
9. Chen YM, Shih JF, Perng RP et al. A randomized trial of different docetaxel schedules in non-small cell lung cancer patients who failed previous platinumbased chemotherapy. Chest 2006; 129: 1031-1038.
10. Camps C, Massuti B, Jiménez A et al. Spanish Lung Cancer Group. Randomized phase III study of 3-weekly versus weekly docetaxel in pretreated advanced nonsmall-cell lung cancer: a Spanish Lung Cancer Group trial. Ann Oncol 2006; 17: 467-472.
11. Machin D, Campbell MJ, Fayers PM, Pinol APY. Sample Size Tables for Clinical Studies. Oxford, Blackwell Publishing 1997.
12. Newcombe RG, Altman DG. Proportions and their differences. In Altman DG, Machin D, Bryant TN et al. (eds), Statistics with Confidence, 2nd edition. London: British Medical Journal 2000; 45-56.
13. Fairclough DL. Design and Analysis of Quality of Life Studies in Clinical Trials. London: Chapman & Hall 2002; 101-104.
14. McCarthy JS, Tannock IF, Degendorfer P et al. A phase II trial of docetaxel and cisplatin in patients with recurrent or metastatic nasopharyngeal carcinoma. Oral Oncol 2002; 38: 686-690.
15. Chua DT, Sham JS, Au GK. A phase II study of docetaxel and cisplatin as firstline chemotherapy in patients with metastatic nasopharyngeal carcinoma. Oral Oncol 2005; 41: 589-595.
16. American Society of Clinical Oncology. Outcomes of cancer treatment for technology assessment and cancer treatment guidelines. J Clin Oncol 1996; 14: 671-679.
17. Silvestri G, Pritchard R, Welch HG. Preferences for chemotherapy in patients with advanced non-small cell lung cancer: descriptive study based on scripted interviews. BMJ 1998; 317: 771-775.
18. Johnson FM, Garden A, Palmer JL et al. A phase II study of docetaxel and carboplatin as neoadjuvant therapy for nasopharyngeal carcinoma with early T status and advanced N status. Cancer 2004; 100: 991-998.
19. Hui EP, Ma BB, Leung SF et al. Randomized phase II trial of concurrent cisplatinradiotherapy with or without neoadjuvant docetaxel and cisplatin in advanced nasopharyngeal carcinoma. J Clin Oncol 2009; 27: 242-249.